This study investigates combining dexamethasone with PPAR agonist GW7647 to improve glucocorticoid efficacy and reduce metabolic side effects in rheumatoid arthritis models.

Arthritis & Rheumatology · Sep 7, 2026Peer-reviewedImmunology

CCR1 inhibition sensitizes multiple myeloma cells toglucocorticoid therapy

Bert Luyckx, Maaike Van Trimpont, Fien Declerck, Eleni Staessens, Annick Verhee, Sara T’Sas, Sven Eyckerman, Fritz C. Offner, Pieter Van Vlierberghe, Steven Goosens, Dorien Clarisse, Karolien De Bosscher

This study shows that inhibiting CCR1 enhances the effectiveness of glucocorticoid therapy in multiple myeloma by reversing resistance mechanisms.

Pharmacological Research · Mar 23, 2025Peer-reviewedCancer Biology

PPARalpha-ERRalpha crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression

Milton Boaheng Antwi, Sander Lefere, Dorien Clarisse, Lisa L. Koorneef, Anneleen Heldens, Louis Onghena, Kylian Decroix, Daria Fijałkowska, Jonathan Thommis, Madeleine Hellemans, Anne Hoorens, Anja M. Geerts, Lindsey Devisscher, Karolien De Bosscher

This study shows that targeting PPAR and ERR receptors reduces liver fat, fibrosis, and inflammation in MASLD models, suggesting a new therapeutic strategy.

Metabolism · Dec 30, 2024Peer-reviewedPharmacology & Toxicology

Crosstalk interactions between transcription factors ERRalpha and PPARalpha assist PPARalpha-mediated gene expression

Sofie J. Desmet, Jonathan Thommis, Tineke Vanderhaeghen, Edmee Vandenboorn, Dorien Clarisse, Yunkun Li, Steven Timmermans, Daria Fijałkowska, Dariusz Ratman, Evelien Van Hamme, Lode De Cauwer, Bart Staels, Luc Brunsveld, Frank Peelman, Claude Libert, , Karolien De Bosscher

The paper identifies crosstalk between ERRalpha and PPARalpha transcription factors, showing ERRalpha can act as both a repressor and activator of PPARalpha-mediated gene expression.

Molecular Metabolism · Apr 15, 2024Peer-reviewedMolecular Biology